Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
parietaria monomeric carbamylated allergoid
- Development stage
- Phase 3
- Lead developer
- Lofarma
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Sublingual
01
Overview
Parietaria (marketed under the brand name Lais) is a sublingual immunotherapy (SLIT) product developed by Lofarma S.p.A. for the treatment of allergic conditions triggered by *Parietaria* pollen. The active ingredient is a monomeric carbamylated allergoid (CMA), which is produced by chemically modifying *Parietaria* pollen allergens through carbamylation. This modification is designed to reduce the allergen's IgE-binding capacity (decreasing allergenicity and the risk of systemic reactions) while preserving its immunogenicity to induce long-term desensitization. Formulated as orosoluble tablets, it is indicated for the treatment of seasonal allergic rhinitis, allergic conjunctivitis (oculorhinitis), and allergic asthma in patients sensitized to *Parietaria* pollen.
- Brand names
- Lais
- Other names
- Parietaria pollen extractParietaria allergoidLais Parietariamonomeric carbamylated allergoid
02
Targets
Parietaria-specific B-cell receptorParietaria-specific CD4+ T-cell receptorParietaria-specific Immunoglobulin E
Beyond the preview
Go deeper on parietaria monomeric carbamylated allergoid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on parietaria monomeric carbamylated allergoid.